BSX

SEC source: 0001225208-25-008761 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,035

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.57 to $101.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-008180 · doc4.xml · derivative · entry 5

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2027-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-008180 · doc4.xml · nonDerivative · entry 3

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,342

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.86 to $98.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-008180 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,097

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.86 to $98.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-008180 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 228,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

SEC source: 0001225208-25-007716 · doc4.xml · derivative · entry 5

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 50,000 shares

Expires 2027-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-007716 · doc4.xml · nonDerivative · entry 3

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,342

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.32 to $106.27, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-007716 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,512

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.32 to $105.25 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-007716 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 228,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

SEC source: 0001225208-25-006988 · doc4.xml · derivative · entry 3

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,090 shares

Expires 2025-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-25-006988 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,289

SEC source: 0001225208-25-006988 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,817

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-006987 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,979

SEC source: 0001225208-25-006985 · doc4.xml · derivative · entry 10

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,177

Underlying: Common Stock · 3,176 shares

Expires 2026-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-25-006985 · doc4.xml · derivative · entry 9

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,175

Underlying: Common Stock · 6,176 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-006985 · doc4.xml · derivative · entry 8

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,009

Underlying: Common Stock · 1,009 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-25-006985 · doc4.xml · derivative · entry 7

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,952

Underlying: Common Stock · 6,952 shares

Expires 2028-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-25-006985 · doc4.xml · nonDerivative · entry 5

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,600

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.16 to $105.10, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-006985 · doc4.xml · nonDerivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-006985 · doc4.xml · nonDerivative · entry 3

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-006985 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-006985 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,552

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F2 · balance_after: Includes shares acquired on June 30, 2025 under the Company's Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-25-006986 · doc4.xml · derivative · entry 4

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 50,000 shares

Expires 2027-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-006986 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,342

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.16 to $105.10, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-006986 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 228,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

SEC source: 0001225208-25-006892 · doc4.xml · nonDerivative · entry 1

FUJIMORI YOSHIAKI · CIK 0001233160 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,081

SEC source: 0001225208-25-006805 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,479

SEC source: 0001225208-25-006332 · doc4.xml · derivative · entry 2

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,173

Underlying: Common Stock · 22,173 shares

Expires 2035-07-01

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on July 1, 2026, the first anniversary of the date of grant.

SEC source: 0001225208-25-006332 · doc4.xml · derivative · entry 1

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2029-07-01

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2026, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2026, the first anniversary of the date of grant.

SEC source: 0001225208-25-006331 · doc4.xml · derivative · entry 4

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 50,000 shares

Expires 2027-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-006331 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,342

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $106.66 to $107.37, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-006331 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 228,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

SEC source: 0001225208-25-006330 · doc4.xml · derivative · entry 3

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,036 shares

Expires 2025-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-25-006330 · doc4.xml · nonDerivative · entry 2

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,451

SEC source: 0001225208-25-006330 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,403

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-005721 · doc4.xml · derivative · entry 4

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 56,372 shares

Expires 2027-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-005721 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,342

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.46 to $103.42, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-005721 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 234,714

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

SEC source: 0001225208-25-005681 · doc4.xml · derivative · entry 7

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 148,221

Underlying: Common Stock · 49,407 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-25-005681 · doc4.xml · derivative · entry 6

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,212 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,476,882

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.83 to $103.825 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,566,803

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.83 to $104.755, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,641,325

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.

SEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,591,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.

SEC source: 0001225208-25-005546 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,479

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.59 to $104.615, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-005376 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,367

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024.

SEC source: 0001225208-25-004936 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,025

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-25-004935 · doc4.xml · nonDerivative · entry 1

WICHMANN DAVID S · CIK 0001268489 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,582

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-25-004934 · doc4.xml · nonDerivative · entry 1

Sununu John E · CIK 0001458974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,723

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-25-004933 · doc4.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,893

Underlying: Common Stock · 605 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $62,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.exercise_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $62,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.expiration_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $62,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.